19 July 2019 - First biosimilar Avastin and Herceptin products to launch in the United States.

Amgen and Allergan today announced that Mvasi (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), and Kanjinti (trastuzumab-anns), a biosimilar to Herceptin (trastuzumab), are now available in the United States (U.S.).

The Wholesale Acquisition Cost (WAC) of both Mvasi and Kanjinti will be 15% lower than their reference products. Mvasi is being made available at a WAC of $677.40 per 100 mg and $2,709.60 per 400 mg single-dose vial, 15% less than the WAC for Avastin. Kanjinti is being made available at a WAC of $3,697.26 per 420 mg multi-dose vial, 15% below the WAC of Herceptin. At launch, Mvasi is priced 12% below the current Avastin Average Selling Price (ASP) and Kanjinti is priced 13% below the current Herceptin ASP. Both products will be available from both wholesalers and specialty distributors.

Read Amgen press release